Clinical Trial

To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or the combination of fimasartan, atorvastatin, and ezetimibe.
Trial Details
NCT Number NCT07685054
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Essential Hypertension, Primary Hypercholesterolemia
Enrollment 12,700 participants
Start Date 2026-08-01
Primary Completion 2029-08-15 (estimated)
Study Completion 2029-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-06